Rodman & Renshaw Maintains Abiomed Market Underperform, $10 PT

Rodman & Renshaw maintained its Abiomed ABMD Market Underperform rating and $10 price target in a research report published today. In the report, Rodman & Renshaw states, "Our due diligence checks with physicians suggest that the consensus view is “for the right patient the Impella works great.” The operative word here is “right.” Properly identifying the right patient subset whether in high-risk PCI or AMI shock remains problematic. It is unclear how the Impella line of products will become mainstream." Shares of Abiomed were trading at $12.01 at the time of posting, down 21.19% from Wednesday's market close.